Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
Provided By GlobeNewswire
Last update: Mar 31, 2025
-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial -
- Halneuron® CINP P2b study interim data readout is expected in Q4 2025 -
Read more at globenewswire.comNASDAQ:DWTX (10/27/2025, 1:29:01 PM)
5.96
+0.08 (+1.36%)
Find more stocks in the Stock Screener
